TY - JOUR
T1 - Transitional cell bladder carcinoma with presentation mimicking ovarian carcinoma
AU - Erickson, Deborah R.
AU - Dabbs, David J.
AU - Olt, George J.
PY - 1996/5
Y1 - 1996/5
N2 - In the case described here, the patient's initial presentation suggested ovarian carcinoma. She had recurrent ascites, a pelvic mass, elevated CA- 125, and extensive peritoneal carcinomatosis with transitional cell histology. The presence of hematuria prompted a cystoscopy, which revealed the true site of origin to be the urinary bladder rather than ovaries. This presentation is extremely rare for bladder cancer. Since transitional cell tumors from the bladder have a much worse prognosis than those of ovarian origin, it is important to identify the primary site correctly. Therefore, cystoscopy is essential for patients with hematuria, and should be considered in cases of apparent primary peritoneal carcinoma with transitional cell histology.
AB - In the case described here, the patient's initial presentation suggested ovarian carcinoma. She had recurrent ascites, a pelvic mass, elevated CA- 125, and extensive peritoneal carcinomatosis with transitional cell histology. The presence of hematuria prompted a cystoscopy, which revealed the true site of origin to be the urinary bladder rather than ovaries. This presentation is extremely rare for bladder cancer. Since transitional cell tumors from the bladder have a much worse prognosis than those of ovarian origin, it is important to identify the primary site correctly. Therefore, cystoscopy is essential for patients with hematuria, and should be considered in cases of apparent primary peritoneal carcinoma with transitional cell histology.
UR - http://www.scopus.com/inward/record.url?scp=0029866172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029866172&partnerID=8YFLogxK
U2 - 10.1006/gyno.1996.0143
DO - 10.1006/gyno.1996.0143
M3 - Article
C2 - 8626151
AN - SCOPUS:0029866172
SN - 0090-8258
VL - 61
SP - 294
EP - 296
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 2
ER -